Showing 1214 results
- Key Release /Der Nettoumsatz steigt im Geschäftsjahr um 5% (kWk[1], +6% USD) dank starker Performance der Wachstumstreiber: Die Geschäftseinheit Pharmaceuticals wächst um 7% (kWk), getragen von Cosentyx mit…
- Media Release /Crizanlizumab is a monthly infusion under development to prevent pain crises (also called vaso-occlusive crises, or VOCs) in patients with sickle cell disease Sickle cell VOCs, which are…
- Media Release /reSET-O(TM)* is the first US FDA-cleared prescription digital therapeutic for patients with Opioid Use Disorder Cleared by the FDA in December, reSET-O is available immediately As part of a…
- Key Release /Adds 177Lu-PSMA-617, a potential first-in-class radioligand therapy in Phase III development for metastatic castration-resistant prostate cancer (mCRPC) Strengthens leadership in nuclear…
- Media Release /Basel, December 21, 2018 - Novartis today announced that the European Commission (EC) approved an expanded indication for Kisqali® (ribociclib), the CDK4/6 inhibitor with the largest body of…
- Media Release /Proposed acquisition builds on existing agreement with CellforCure for contract manufacturing of Novartis leading CAR-T cell therapy Kymriah® (tisagenlecleucel) and recent successful completion of…
- Key Release /Susanne Schaffert, Ph.D., President, AAA, an established Novartis executive, named new CEO, Novartis Oncology Basel, December 20, 2018 - Novartis announced today that Susanne Schaffert, Ph.D.,…
- Media Release /Agreement covers biosimilar insulins in early and clinical development for the top three selling branded insulins by sales: glargine, lispro and aspart Over 400 million people worldwide have…
- Media Release /Acquisition further expands Alcon's portfolio of comprehensive solutions for patients with dry eye Tear Film's iLux® Device offers innovative, customizable treatment for Meibomian Gland…
- Media Release /The EC approval underscores the long-term safety and efficacy of Xolair demonstrated in clinical studies and by 13 years of real-world use in Europe[1] Xolair® (omalizumab) prefilled…